Cancer Weekly articles from September 2004

Cancer Weekly archives from September 2004

Conversion of irinotecan to SN-38 in plasma characterized.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- The conversion of irinotecan to SN-38 has been characterized in human plasma. "Irinotecan is an active cytotoxic agent for various cancers, and is converted to SN-38, its most active metabolite, by...

Antiangiogenic agents are important adjuncts to conventional chemotherapy.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Antiangiogenic agents are important adjuncts to conventional chemotherapy. According to recent research published in the European Journal of Cancer, "angiogenesis is an obligatory event for the...

Select genes signal the advent of cisplatin resistant esophageal cancer.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Select genes signal the advent of cisplatin resistant esophageal cancer. "To clarify the molecular basis of acquired cisplatin (CDDP) resistance in esophageal squamous cell carcinoma (ESCC), we used...

Novel cell line may aid research.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- A novel myeloma cell line has been generated and characterized. In a recent study from Japan, the MM cell line "MOLP-8 carrying the t(11;14) (q13;q32) was established from the peripheral blood of a...

Marimastat, captopril and fragmin combine to aid those with advanced cancer.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Marimastat, captopril and fragmin combine to aid those with advanced cancer. "Marimastat, low molecular weight heparins and captopril have antiangiogenic activity in vitro and in animal models. We...

First patients enter pivotal phase II study of clofarabine.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Bioenvision, Ltd., (BIV) has announced that the first adult patients have been dosed on a pivotal European phase II study to evaluate its lead leukemia compound, clofarabine, in the treatment of adults...

Hair dye may be greater risk for adult acute leukemia than previously reported.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- According to research from the U.S., permanent hair dye use for 15 years or more may have a more significant impact on adult acute leukemia risk and other hematopoietic cancers than previously reported....

Aranesp receives positive regulatory opinion for extended dosing in Europe.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Amgen, Inc., (AMGN) announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to expand the marketing authorization for Aranesp (darbepoetin alfa)...

Autoclave sterilization produces acrylamide in rodent diets.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Autoclave sterilization produces acrylamide in rodent diets, which has implications for toxicity testing. According to recent research from the United States, "Acrylamide (AA) is a neurotoxic and...

Gene-deleted oncolytic adenovirus vector activates cancer therapy.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Gene-deleted oncolytic adenovirus vector activates cancer therapy. "Viruses that replicate selectively in cancer cells constitute an exciting new class of anticancer agent. The conditionally...

University researcher awarded DOD grant to study prostate cancer drug.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Richard Valicenti, MD, associate professor of radiation oncology, Jefferson Medical College of Thomas Jefferson University and Jefferson's Kimmel Cancer Center in Philadelphia, has been awarded a grant...

DPPH-radical scavengers are isolated from soybean miso.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- 8-hydroxyglycitein and 6-hydroxydaidzein have been isolated from soybean miso. According to A. Hirota and colleagues of the University Shizuoka, "We isolated from soybean miso 8-hydroxyglycitein and...

Clever surgery turns an ankle into a "knee" after removing child's bone tumor.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- While limb-sparing surgery for bone cancer is becoming more common, very young children with bone cancer face significant challenges and have limited surgical options. A page in the August 19,...

Cancer study at Pratt & Whitney to take more time and money.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Researchers have doubled the scope of their investigation into brain cancer cases at jet-engine maker Pratt & Whitney and are requesting another 2 years and an additional $4 million to complete the...

Marijuana ingredient inhibits pathway required for brain tumor blood vessels.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Cannabinoids, the active ingredients in marijuana, restrict the sprouting of blood vessels to brain tumors by inhibiting the expression of genes needed for the production of vascular endothelial growth...

Mesenchymal stem cells have antitumor effect in rat glioma model.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Genetically engineered mesenchymal stem cells have an antitumor effect in a rat glioma model. "The prognosis of patients with malignant glioma is extremely poor, despite the extensive surgical...

Circulating tumor cells in blood indicate more aggressive disease.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Patients with advanced breast cancer who have more than five circulating tumor cells in the blood may have a more dangerous form of the disease, according to oncologists at the University of Texas M.D....

Developing preventive strategies might help cut costs of advanced disease.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Researchers have "estimated lifetime cost of treatment for patients in the United Kingdom presenting with stage IV breast cancer." A panel of oncologists completed a questionnaire about their major...

EGR3 involved in estrogen-signaling pathway in breast cancer.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- EGR3 is involved in the estrogen-signaling pathway in breast cancer. According to recent research from Japan, "Estrogen has been closely associated with the genesis and malignant progression of...

FDA approves early stage breast cancer drug.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Pharmaceutical company Aventis has announced that it has won U.S. Food and Drug Administration approval of its drug Taxotere for treatment of women with early stage breast cancer. The FDA approval...

New breast cancer clinical trial program commences.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Two new multicenter studies to evaluate Bioenvision's (BIV) Modrenal (trilostane), in pre- and post-menopausal forms of breast cancer, were announced. The phase II (pre-menopausal) and phase IV...

New screening technologies need further evaluation.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- New screening technologies for breast cancer have advantages, but their regular use needs further evaluation, researchers report. L. Irwig and colleagues at the University of Sydney "systematically...

Protein found essential for epithelial-mesenchymal transition and metastasis.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Researchers in Germany have demonstrated that the protein NF-kB is required for epithelial-mesenchymal transition and metastasis by breast cancer tumors. The prognosis for cancer patients is...

Race a factor in breast reconstruction after mastectomy.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- African American women are significantly less likely to be treated with breast reconstruction after mastectomy than Caucasian, Asian, and Hispanic women, independent of age and clinical and...

Screening high-risk women for cancer does not negatively impact short-term QOL.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- A study from The Netherlands found that screening women at high risk for breast cancer does not negatively affect their short-term, health-related quality of life. "The effectiveness of intensive...

Screening underutilized by immigrant women in Canada.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Lack of information, modesty, and a false sense of security may prevent women from immigrant backgrounds from having regular clinical breast examinations, according to a study by University of Toronto...

Study does not support protective role for circulating lignans.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Study findings from the U.S. suggest lignan concentrations in serum do not contribute to protection against breast cancer. "It has been proposed that phytoestrogens protect against breast cancer....

Study finds mammography has low risk of recall for false-positive findings.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- A new long-term study determined that over 20 years, only one in five women who have mammograms every 2 years will have to undergo follow-up evaluation for a false-positive finding. And only 1 in 16...

Study linking sucrose and breast cancer questioned by sugar trade organization.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- In response to a recent study published in the journal Cancer Epidemiology, Biomarkers and Prevention, the Sugar Association is questioning the study's claim that breast cancer is connected to sucrose...

gamma Synuclein stimulates hormone-responsive mammary tumorigenesis.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- According to a study from the U.S., gamma synuclein stimulates hormone-responsive mammary tumorigenesis. "Synucleins are emerging as central players in the formation of pathologically insoluble...

Trastuzumab-related cardiotoxicity characterized.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Trastuzumab-associated cardiotoxicity has been characterized in breast cancer patients. "Trastuzumab (Herceptin) is a humanized monoclonal antibody that specifically targets HER2-positive breast...

Biopharmaceutical company reports improved first quarter financial results.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Repligen Corporation (NASDAQ:RGEN) reported results for the first quarter of fiscal year 2005 ended June 30, 2004. Total revenue for the quarter was $2,809,000 compared to total revenue of...

Drug delivery developer reports quarterly finances, clinical pipeline update.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Acusphere, Inc., (ACUS) reported financial results for the second quarter ended June 30, 2004, and commented on its operational progress. The company's financial results for the second quarter of...

Fuzeon maker reports strong Q4 and year-end results.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Chronimed, Inc., (CHMD) reported record revenue and earnings for the fourth quarter and year ended July 2, 2004. Total reported company revenue for the 14-week quarter ending July 2, 2004 was a...

Genta announces second-quarter 2004 financial results.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Genta, Inc., (GNTA) announced financial results for the second quarter ended June 30, 2004. The company reported revenues of $1.6 million for the quarter, and a net loss of $29.2 million or $0.37...

Pharmaceutical company reports second quarter, clinical development results.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Progenics Pharmaceuticals, Inc., (NASDAQ: PGNX) announced its results of operations for the second quarter ended June 30, 2004, and first half of 2004. The company also provided an update of its...

MAP2 facilitates classification of neuroepithelial tumors.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- MAP2 expression patterns can be used to distinguish different types of neuroepithelial malignancies. "Complex and variable morphological phenotypes pose a major challenge to the histopathological...

New web site launched for online orders of NMP22 BladderChek Test.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Matritech, Inc., (MZT) announced the launch of its new web site at www.matritech.com to allow physicians to order Matritech's NMP22 BladderChek Test online. The web site will also provide updated...

Copper-containing hydroxylapatite can retain antibiotic.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Researchers in France report on their study of the release of anthracyclines adsorbed on copper-treated hydroxylapatites. According to R.A. Bacha and colleagues, "Anthracyclines are antibiotics...

ICTs exert opposing activities that can affect host defense systems.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Isothiocyanates (ITCs) affect tumor necrosis factor-alpha (TNF-alpha) production by J774A.1 (BALB/c macrophage) cells. According to a study from Japan, "The effects of ITCs on tumor TNF-alpha...

Poor outcomes of photodynamic therapy in basal cell carcinomas are explored.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- The penetration of 5-aminolevulinic acid through basal cell carcinoma has been evaluated. According to a study from North Ireland, "Aminolevulinic acid (ALA) is a charged, hydrophilic molecule that...

Sprouty2-GFP has properties of a tumor-suppressor protein.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Overexpression of Sprouty2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. "A strict regulation of hepatocyte growth factor/scatter factor (HGF/SF)-Met signaling is...

New cancer test speeds feedback on results of therapy.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Doctors using new technology can get fast feedback on whether treatments are working for breast cancer victims, a new study shows. The test that counts cancer cells in bloodstreams of patients with...

Period analysis provides up-to-date long-term cancer survival estimates.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Researchers from Sweden reported that period analysis, in most cases, can provide up-to-date long-term cancer survival estimates. "The natural development of cancers as well as the measures to...

BNO69 angiogenesis gene discovery published in journal.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Bionomics Limited announced that research conducted by Bionomics and its collaborators at the Hanson Centre of the Institute of Medical and Veterinary Science (IMVS) in Adelaide, Australia, relating to...

Bovine lactoferrin blocks tumor growth via angiogenic inhibition.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Bovine lactoferrin blocks tumor growth via angiogenic inhibition. According to recent research from Japan, "recent studies have demonstrated that bovine lactoferrin (bLF) suppresses tumor growth and...

Collaboration to develop orally active chloride channel blocker cancer therapy.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- TopoTarget A/S has entered into a collaboration with NeuroSearch (NEUR.CO) to develop the NeuroSearch compound Endovion (NS3728), an orally active chloride channel blocker for the treatment of cancer....

IVAD-related thrombotic complications characterized.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- The adverse thrombotic effects associated with the use of implanted venous access devices (IVADs) have been characterized. IVADs are "routinely used in oncologic patients," scientists in France...

Pharma company reports financial results consistent with earlier guidance.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Onyx Pharmaceuticals, Inc., (NASDAQ:ONXX) reported a net loss of $13.1 million, or $0.38 per share, for the second quarter ended June 30, 2004, compared with a net loss of $11.4 million, or $0.48 per...

Pharmaceutical company announces third quarter financial results.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- OSI Pharmaceuticals, Inc., (NASDAQ:OSIP) announced its financial results for the company's third quarter ended June 30, 2004. The company reported net losses for the third quarter and 9-month...

Proteasome inhibitors show promise for treating cancer in clinical trials.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Proteasome inhibitors show promise for treating cancer in clinical trials. According to recent research published in the journal Clinical Cancer Research, "Bortezomib (PS-341, Velcade, Millennium...

U.K. patient organizations recommends Glivec for inoperapeable tumors.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- The National Institute for Clinical Excellence (NICE) concluded that Glivec (imatinib) should be prescribed in England and Wales, as a first-line option for all people with unresectable (inoperable)...

Binding patterns reveal tumor-specific epitope of epithelial mucin.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1). "Glycosylation determines essential biological functions of...

Dendritic cell and fibroblast fusions possess antitumor effects.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Fusions composed of dendritic cells and fibroblasts transfected with genomic DNA from tumor cells possess antitumor effects. According to a study from Japan and the United States, "Based on several...

Dendritic cell vaccine induces tumoricidal CD8+ cytotoxic lymphocytes.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of...

Epigenetically altered tumor cell vaccine developed.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- An epigenetically altered tumor cell vaccine has been developed. According to a study from the United States, "Functional inactivation of genes critical to immunity may occur by mutation and/or by...

Genetic adjuvants enhance efficacy of vaccine against Her-2/neu tumor antigen.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Genetic adjuvants enhance the efficacy of DNA vaccination against Her-2/neu tumor antigen. According to published research from South Korea, "Certain types of malignant tumors overexpress Her-2/neu,...

IL-18-secreting fibroblasts prolong survival of tumor-bearing mice.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Interleukin-18-secreting fibroblasts loaded with an epitope peptide generated tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice. "There is currently much...

Immunotherapy of cancer reviewed.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Scientists review the immunotherapy of cancer in a recent issue of the Journal of Cancer Research and Clinical Oncology. "Until the end of the 19th century the possibility that a tumor could be...

Non-CpG motif oligonucleotides for cancer vaccination developed.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Scientists have developed immunomodulatory six base-length non-CpG motif oligonucleotides for cancer vaccination. According to recent research from Canada, "We have previously described a novel...

Pemetrexed (ALIMTA) is novel multitargeted antineoplastic agent.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Pemetrexed (ALIMTA) is a novel multitargeted antineoplastic agent. "Pemetrexed (ALIMTA, LY231514, MTA) is a novel antimetabolite that inhibits at least three enzymes involved in the folate pathway....

Plasmid DNA in microparticles stimulates durable T cell responses.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor-associated antigen cytochrome...

T-cell responses in patients vaccinated with melanoma vaccine reported.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Researchers report the results of an analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates in a recent issue of Cancer Immunology...

AGUS coexisting with ASCUS signals clinically significant pathology.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Detection of atypical glandular cells of undetermined significance, especially along with atypical squamous cells of undetermined significance, by cervical cytologic screening is indicative to...

Discrepancies found between blot hybridization and PCR for HPV genome analysis.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- In the process of investigating the etiologic role of human papillomavirus (HPV) in cervical cancer, researchers in Japan found blot hybridization analysis of the HPV genome gave them different results...

New DNA vaccine targets proteins expressed in cervical cancer cells.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Johns Hopkins Medical Institutions pathologists have developed a new DNA vaccine that targets proteins expressed in cervical cancer cells. Their work was described in the August 2004 issue of the...

Second Pap smear + HPV-DNA testing clarifies atypical glandular cell status.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Women in whom atypical glandular cells are detected via primary Pap smear may benefit from information gained from a second Pap test combined with human papillomavirus DNA testing, say researchers in...

FDA approves of Avastin manufacturing at Vacaville, California, facility.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Genentech, Inc., (DNA) announced that the U.S. Food and Drug Administration (FDA) approved the supplemental biologics license application for the manufacturing of Avastin (bevacizumab) bulk drug...

CD40 hold potential for B-CLL therapy.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- CD40 holds potential for B-CLL therapy. According to a study from the United States, "Despite encouraging scientific and therapeutic advances, chronic lymphocytic leukemia (CLL) principally remains...

Agencies create new breast cancer support mechanism.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- This summer marks the launch of a new collaboration between the Tarrant County Affiliate of the Susan G. Komen Foundation and Cancer Care Services (CCS). The effort - the Breast Cancer Navigator -...

Agreement signed for fourth generation LHRH antagonist D-63153.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- AEterna Zentaris, Inc., (AEZ; AEZS) announced that its German subsidiary Zentaris GmbH and Spectrum Pharmaceuticals, Inc., (SPPI) have entered into a licensing and collaboration agreement on a fourth...

Drug discovery alliance focused on cancer.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Array BioPharma, Inc., (ARRY) and QLT, Inc., (QLTI; QLT) announced the initiation of a drug discovery collaboration to create a series of small molecule therapeutics aimed at important cancer targets...

Hyaluronan pairs with CD44 to encourage colon carcinoma cell invasion.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Hyaluronan pairs with CD44 to encourage colon carcinoma cell invasion. According to a study from the United States, "hyaluronan (HA) and its biosynthetic enzymes, HA synthases (HAS1, 2, and 3) are...

New guideline does not recommend chemotherapy for stage II colon cancer.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- The American Society of Clinical Oncology (ASCO) has developed a set of recommendations to address whether patients who have had successful surgery for stage II colon cancer should be offered adjuvant...

Colorectal cancer risk greater in adenoma patients, Netherlands study shows.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- When compared to the general population, researchers from the Netherlands found that adenoma patients are at greater risk for colorectal cancer. "Colorectal cancer incidence after adenoma removal...

Stool-based DNA testing reviewed.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- The utility of stool-based DNA testing for colorectal cancer has been reviewed. "Despite a variety of screening strategies and recent trends showing death rate stabilization, colorectal cancer still...

Emodin inhibits tumor invasion through suppression of AP-1 and NF-kappa B.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Emodin inhibits tumor invasion through suppression of activator protein- 1 and NF-kappa B. "3-Methyl-1,6,8-trihydroxyanthraquinone (emodin) is an active component from the rhizome of Rheum palmatum,...

Chinese folk medicine Shiraiachrome A routs new vessel growth.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- The Chinese folk medicine Shiraiachrome A routs new vessel growth. According to published research from the Peoples Republic of China, "the Chinese folk medicine Shiraia bambusicola has long been...

Cumulative dose of epirubicin can be related to cardiotoxicity.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- The cumulative epirubicin dose - rather than high-dose paclitaxel - is associated with impaired cardiac function in breast cancer patients. According to a study from Italy, "The aim of the study was...

CMV prophylaxis following BMT has changed the natural history of the disease.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Cytomegalovirus prophylaxis following bone marrow transplant has changed the natural history of the disease. "Cytomegalovirus (CMV) is a well-known cause of disease occurring after bone marrow...

Late CMV infection associated with SCT history of early CMV infection.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Late CMV infection is associated with donor lymphocyte infusion history of early CMV infection. "An increased incidence of late cytomegalovirus (CMV) infection has been reported during the last...

Sale of dermatology assets to Bradley Pharmaceuticals.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Quintiles Transnational Corp. announced the completion of the previously announced sale of assets relating to its specialty dermatology products company, Bioglan Pharmaceuticals, to BDY Acquisition...

Tumor vascularity is a major player in cutaneous melanoma progression.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- Tumor vascularity is a major player in cutaneous melanoma progression. "The natural course of cutaneous melanoma (CM) is determined by its metastatic spread and depends on tumor thickness,...

Genetics company extends collaboration with Chinese University of Hong Kong.
September 7, 2004... 2004 SEP 7 - (NewsRx.com & NewsRx.net) -- SEQUENOM, Inc., (NASDAQ:SQNM) announced a research collaboration with The Chinese University of Hong Kong (CUHK) for further development of prenatal diagnostic applications on the MassARRAY platform....